Clinical trial
An Open-label, Single-arm, Phase II Study to Investigate the Efficacy and Safety of Niraparib Combined With Anlotinib Maintenance Retreatment in PSR Ovarian Cancer Patients, Who Have Previously Received PARPi Maintenance Treatment.
NCT05385068 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-arm, Phase II Study to Investigate the Efficacy and Safety of Niraparib Combined With Anlotinib Maintenance Retreatment in PSR Ovarian Cancer Patients, Who Have Previously Received PARPi Maintenance Treatment.
- Lead sponsor
- Peking Union Medical College Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2022
- Completion date
- September 30, 2024
- Enrollment
- 35 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
epithelial ovarian cancer